Developing a new research institute

The importance of significant genetic variations between breast cancers

Results of 5 year phase III randomised trial treating localised prostate cancer

Diagnosis while pregnant should not lead to treatment delay or pregnancy termination

DDFMISO trial confirms significant negative prognostic value of tumour hypoxia

'Survivor passport' for survivors of childhood leukaemia

Progression of childhood cancers in Europe

Expanding access to crizotinib using a biomarker-driven approach

Rova-T: First ‘targeted’ treatment for small cell lung cancer shows promise

Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC

Latest in lung cancer from ECC 2015

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic review